Supira Medical, a Shifamed portfolio company based in Los Gatos, Calif., is developing the Supira System, an investigational next-generation pVAD intended for HRPCI and cardiogenic shock. The company recently completed enrollment of its U.S. SUPPORT I Early Feasibility Study, enrolling 15 patients across four clinical sites, and reports the Supira System has benefited 85 HRPCI patients to date. The device is investigational and not approved for sale in the U.S. or elsewhere. Supira plans to expand its clinical programs for both HRPCI and cardiogenic shock, including the SUPPORT II U.S. Pivotal Study for HRPCI that will be used to seek FDA PMA approval. The company aims to use new capital to accelerate those clinical programs and further validate its low-profile, high-flow technology platform. Supira Medical is advancing the Supira System, a percutaneous ventricular assist device (pVAD) featuring a novel low-profile, high continuous-flow design intended to provide full hemodynamic support initially for high-risk percutaneous coronary interventions and subsequently for cardiogenic shock. The system is built with a 10F profile to minimize vascular complications and incorporates multiple sensors for real-time pressure measurements. The Supira System is for investigational use only and is not for sale in the U.S. or outside the U.S. Supira is led by President and CEO Dr. Nitin Salunke and is a portfolio company of Shifamed, LLC. The company plans to expand its currently enrolling OUS studies, plan for U.S. studies, and prepare for a U.S. pivotal study submission. It raised $40M in Series D financing to support those clinical and regulatory activities. Supira Medical is developing a next-generation percutaneous ventricular assist device (pVAD) intended to provide temporary mechanical circulatory support for high-risk patients. The device is aimed for use during interventional procedures such as stent placement or angioplasty and to treat patients suffering from cardiogenic shock following severe heart attacks. The company is led by CEO Dr. Nitin Salunke and is a Shifamed portfolio company based in Los Gatos, CA. Supira plans to finalize product development and initiate a first-in-human clinical study for its pVAD. Financially, the company recently completed a financing round to support those activities. Supira Medical is focused on developing a next-generation percutaneous ventricular assist device (pVAD) for use in high-risk patients undergoing interventional procedures. The company was formed as the newest portfolio company of Shifamed and is located in Shifamed's facility in Silicon Valley. Jean Orth was appointed CEO in December 2017 and brings more than 25 years of cardiology-centric medical device experience. Supira closed a $15.5M financing that officially closed on April 25, 2018 to support its early development efforts. The round was led by The Capital Partnership with participation from Cormorant Asset Management and Shifamed Angels. Shifamed's incubator track record includes multiple exits, providing an experienced sponsor and potential exit pathways for its portfolio companies.

Total raised

$206M

Funding rounds

4

Latest round

Series E

Latest activity

Mar 2025